ESLA Stock — Estrella Immunopharma Inc.: Cash, EV, Pipeline

Share price

$0.53

Market cap

$23.0M

Cash

$0.1M

Enterprise value

$22.9M

Balance sheet

Cash	$0.1M
Debt	$0.0M
Net cash	$0.1M
Enterprise value	$22.9M
Basic shares	43.0M shares
Fully diluted shares	56.9M shares
Fully diluted market cap	$30.2M
Cash per share	$0.00

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ESLA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 11 - Mar 25	EB103	Phase 2	B-Cell Non-Hodgkin's Lymphoma (NHL); Lymphoma, Non-Hodgkins; Lymphomas Non-Hodgkin's B-Cell	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

EB103

Phase 1 · Active Modality: T-cell therapy (ARTEMIS)

Target CD19

Partnerships Eureka Therapeutics (ARTEMIS T-cell technology; clinical trial services agreement up to $33.5M for STARLIGHT-1)

Indications

relapsed or refractory B-cell non-Hodgkin lymphoma (Phase 1)

Catalysts

— H1 2027

Status note Lead product candidate. T-cell therapy targeting CD19. FDA IND cleared March 2, 2023. Phase I dosing completed November 2025; 11 patients dosed total (9 Phase I, 2 Phase II dosed Jan and June 2026).

EB104

Preclinical · Active Modality: T-cell therapy (ARTEMIS)

Target CD19, CD22

Partnerships Eureka Therapeutics (ARTEMIS T-cell technology)

Indications

CD19-positive cancers (Preclinical)

Status note Dual-targeting ARTEMIS T-cells targeting CD19 and CD22; intended to address lower CD19 surface density and CD19 antigen-loss relapse. Company plans to advance EB104 into clinical development.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	EB103
Lead indication	B-Cell Non-Hodgkin's Lymphoma (NHL)
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06343311	Phase 2	Recruiting	Sponsor	ESLA	—	B-Cell Non-Hodgkin's Lymphoma (NHL); Lymphoma, Non-Hodgkins; Lymphomas Non-Hodgkin's B-Cell	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Estrella Biopharma, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ESLA — Estrella Immunopharma Inc.